www.pharmpro.com

www.pharmpro.com
Share

www.pharmpro.com

 •  July 12

Earlier this year, in his first address to Congress, President Trump criticized the FDA’s drug approval process saying the length of time in which drugs need to be approved is “slow and burdensome.” In many cases, the FDA approval process is both long and expensive, which can drive retail prices up for consumers. Many argue that this system...

www.pharmpro.com

 •  June 27

The more adjustments and tools that are required, the greater the possibility for mistakes. In the world of pharmaceutical labeling, radical change has never really occurred, nor is it on the horizon. Changes are predominantly incremental. However, change is most definitely afoot—not revolutionary, but definitely perceptible—directly linked to the...

www.pharmpro.com

 •  April 5

Meiji Seika and Eisai enter into a collaboration for the development and commercialization of safinamide in Parkinson’s disease for Japan and Asia. Eisai Co., Ltd. and Meiji Seika Pharma Co., Ltd. announced today that they have entered into a license agreement for the commercialization of safinamide (development code: ME2125) for the treatment of...

www.pharmpro.com

 •  February 14

The U.S. government and 11 states are seeking as much as $3.3 billion from Novartis over an alleged kickback scheme involving its Exjade and Myfortic drugs, according to documents filed in the U.S. District Court for the Southern District of New York. Specifically, the government claims Novartis and a group of pharmacies submitted 126,802 claims to...